Compare Schwab US Large Cap Growth ETF (SCHG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs TransMedics Group Inc — how do they compare? Schwab US Large Cap Growth ETF trades at $35.64, while TransMedics Group Inc trades at $87.58 (market cap $3.10B). The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SCHG | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $35.83 | $150.42 |
52-Week Low | $28.10 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $35.62, down 0.59% today, with a bullish technical outlook supported by moving averages. The ETF's concentrated portfolio of large-cap growth stocks, particularly in technology, drives performance but introduces concentration risk. Recent news highlights strong historical returns and institutional activity, though some analysts question current valuations.
Outlook remains positive given exposure to AI and technology growth trends, but investors face risks from high concentration in top holdings and sensitivity to interest rate changes. The low 0.04% expense ratio and tax efficiency are key advantages for long-term growth investors.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
